USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PROTEOMTECH, INC.
Address:
PROTEOMTECH, INC.
5980 HORTON ST, STE 405
EMERYVILLE, CA 94608
Phone:
N/A
URL:
N/A
EIN:
152218403
DUNS:
110482911
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $500,000.00 5
SBIR Phase II $750,197.00 1

Award List:

Recombinant h-VEGI as an Anticancer Therapeutic

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Blocking or inhibiting blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human endothelial cells have demonstrated that it is a potent… More

Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$750,197.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human endothelial cells have demonstrated that it is… More

Bioengineering Prourokinase for Improved Fibrinolysis

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to bioengineer a mutant variant of prourokinase (proUK) with improved therapeutic properties for treatment of acute myocardial infarction(AMI). ProUK is unique among thrombolytic agents in that it is stable as an inert zymogen in… More

Recombinant HBxAg Production For Anti-cancer Therapeutic

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by investigator): Chronic infection with hepatitis B virus (HBV) is associated with a high incidence of liver diseases, including hepatocellular carcinoma (HCC). Hepatitis B virus x antigen (HBxAg), one of the four proteins encoded by the virus, stimulates virus gene expression… More

Recombinant Des-Kringle Derivatives of Plasmin for Treatment of Peripheral Arteri

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Xlnli H. Lin
Abstract:
Thrombolytic treatment with plasminogen activators (PA) such as tissue plasminogen activator (tPA) has been used not only for treatment of acute myocardial infarction, but also peripheral arterial occlusion (PAO). However, the risk of life-threatening intracranial hemorrhage is measurably high… More

p53 Fusion Protein as an Oncology Therapeutic

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a cancer therapeutic. World wide 10 million people are diagnosed every year with cancer. 50% of human cancers involve a mutation in the p53 gene. In addition, these… More